SYNBIOTICS CORP
10-Q, EX-27, 2000-11-14
IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
Previous: SYNBIOTICS CORP, 10-Q, EX-10.74.2, 2000-11-14
Next: GRANDBANC INC, 10QSB, 2000-11-14



<TABLE> <S> <C>

<PAGE>

<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THE
CONDENSED CONSOLIDATED BALANCE SHEET AS OF SEPTEMBER 30, 2000 AND THE RELATED
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND CASH FLOWS FOR THE NINE
MONTHS ENDED SEPTEMBER 30, 2000 INCLUDED ELSEWHERE IN THIS FORM 10-Q AND IS
QUALIFIED IN ITS ENTIRETY BY REFERENCE TO SUCH FINANCIAL STATEMENTS.
</LEGEND>
<MULTIPLIER> 1,000

<S>                             <C>
<PERIOD-TYPE>                   9-MOS
<FISCAL-YEAR-END>                          DEC-31-2000
<PERIOD-START>                             JAN-01-2000
<PERIOD-END>                               SEP-30-2000
<CASH>                                           1,715
<SECURITIES>                                       617
<RECEIVABLES>                                    4,236
<ALLOWANCES>                                       391
<INVENTORY>                                      6,766
<CURRENT-ASSETS>                                14,548
<PP&E>                                           4,360
<DEPRECIATION>                                   1,521
<TOTAL-ASSETS>                                  47,478
<CURRENT-LIABILITIES>                            8,783
<BONDS>                                         10,743
                            2,510
                                          0
<COMMON>                                        40,065
<OTHER-SE>                                    (17,045)
<TOTAL-LIABILITY-AND-EQUITY>                    47,478
<SALES>                                         25,356
<TOTAL-REVENUES>                                25,678
<CGS>                                           12,439
<TOTAL-COSTS>                                   27,140
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                 913
<INCOME-PRETAX>                                (2,375)
<INCOME-TAX>                                        58
<INCOME-CONTINUING>                            (2,433)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                  (583)
<CHANGES>                                            0
<NET-INCOME>                                   (3,016)
<EPS-BASIC>                                     (0.33)
<EPS-DILUTED>                                   (0.33)


</TABLE>


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission